research use only
Cat.No.S3693
|
In vitro |
DMSO
: 2 mg/mL
(13.14 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 152.11 | Formula | C5H4N4O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 69-89-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Xanthine, Isoxanthine | Smiles | C1=NC2=C(N1)C(=O)NC(=O)N2 | ||
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05888233 | Recruiting | Heart Failure Preserved Ejection Fraction|Resistant Hypertension |
VA Office of Research and Development |
August 2 2023 | Phase 2 |
| NCT05361044 | Recruiting | Liver Transplant Failure |
Hospices Civils de Lyon |
August 22 2022 | Not Applicable |
| NCT05351333 | Recruiting | Spinal Cord Injuries|Polytrauma|Burns |
Spaulding Rehabilitation Hospital|National Institute on Drug Abuse (NIDA) |
August 3 2022 | Not Applicable |
| NCT05256810 | Terminated | Gout |
Alnylam Pharmaceuticals |
February 25 2022 | Phase 1|Phase 2 |
| NCT04676009 | Completed | Carcinoma Non-Small-Cell Lung |
Centre Leon Berard|Claude Bernard University|Lyon Cancer Research Centre|Hospices Civils de Lyon|Inter-university Laboratory of Human Movement Biology |
January 21 2021 | Not Applicable |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.